Press Releases

Summary ToggleProLung Announces Changes to its Board of Directors and Leadership Team to Enhance its Medtech Expertise

June 12, 2019

SALT LAKE CITY, UT / ACCESSWIRE / June 12, 2019 /  ProLung, Inc. ("ProLung" or the "Company"), which is focused on reducing the time to diagnosis for lung cancer patients, announced the appointments of Messers. Jim Hogan, David Nielsen and Don Patterson to enhance the medtech expertise and general

Summary ToggleProLung Announces New Office Location as Anchor Tenant at 'The Labs at Northgate'

June 10, 2019

SALT LAKE CITY, UT / ACCESSWIRE / June 10, 2019 /  ProLung, Inc. ("ProLung" or the "Company"), which is focused on reducing the time to diagnosis for lung cancer patients, announced today it has started construction on a new office and laboratory location at 'The Labs at Northgate' in Salt Lake

Summary ToggleProLung named Med Tech Company of the Year 2019 by Global Health & Pharma

March 08, 2019

ProLung is delighted to be honored as the “Med Tech Company of the Year 2019” by Global Health & Pharma. Our ProLung team views external recognition as further validation of our mission to ‘make a difference in time’ for lung cancer patients who face under-prioritized and highly stigmatized disease

Summary ToggleProLung Announces Preliminary Results from its PL-208 Clinical Trial and Next-Steps

February 01, 2019

SALT LAKE CITY, UT / ACCESSWIRE / February 1, 2019 /  ProLung, Inc. (''ProLung'' or the ''Company''), which is focused on reducing the time to diagnosis for lung cancer patients with its ProLung Test™, yesterday announced the preliminary results of its PL-208 Validation Study and outlined its

Summary ToggleProLung named one of 50 Leading Companies of the Year 2018 by Silicon Review

December 18, 2018

ProLung, Inc. is honored to be named one of the ‘50 leading companies of the year 2018’ by Silicon Review. Furthermore, our interim CEO, Mr. Jared Bauer, is interviewed in their end of the year special issue where he discusses how ProLung is focused on ‘making a difference in time’ for lung cancer

Summary ToggleProLung Announces Voting Results from its 2018 Annual Meeting of Shareholders

December 13, 2018

SALT LAKE CITY, UT / ACCESSWIRE / December 13, 2018 /  ProLung, Inc. (''ProLung'' or the ''Company'') is focused on reducing the time to diagnosis for lung cancer patients. ProLung® conducted its 2018 Annual Meeting of Shareholders (''Meeting'') last week with support from many of the individuals

Summary ToggleProLung Announces Final Results from its PL-209 Repeatability Study

November 21, 2018

SALT LAKE CITY, UT / ACCESSWIRE / November 21, 2018 /  ProLung, Inc. ("ProLung" or the "Company") is focused on reducing the time to diagnosis for lung cancer patients. Today ProLung announced final results from its PL-209 repeatability study. The ProLung Test is designed to produce a personalized

Summary ToggleProLung Announces Preliminary Results of Consent Solicitation

October 23, 2018

Consent Solicitation Clearly Failed to Receive the Required Majority - Steven Eror Falsely Claimed Victory for the Third Time SALT LAKE CITY, UT / ACCESSWIRE / October 23, 2018 / ProLung, Inc. ("ProLung" or the "Company") announced today the preliminary results of the consent

Summary ToggleProLung Announces an Intellectual Property and Regulatory Update

October 11, 2018

SALT LAKE CITY, UT / ACCESSWIRE / October 11, 2018 / ProLung, Inc. ("ProLung" or the "Company") today released a letter to its shareholders with an important intellectual property and regulatory update. ProLung® is pleased to announce receipt of a new Notice of Allowance for our proprietary

Summary ToggleFormer ProLung Directors Support The Company's Interim CEO Jared Bauer And Incumbent Board Of Directors

October 02, 2018

SALT LAKE CITY, UT / ACCESSWIRE / October 2, 2018 / ProLung, Inc. ("ProLung" or the "Company") today disclosed a letter to its stockholders from former ProLung® Board Members Clark Campbell, William Fresh, Rich McKeown, Tim Treu and Dennis Tulane. The complete text of the letter is set forth below.